ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc (BMRN)

59,12
-0,85
(-1,42%)
Beim Schlusskurs: 11 Juli 10:00PM
59,12
0,00
( 0,00% )
Nach Börsenschluss: 12:48AM

BioMarin Pharmaceutical Inc (BMRN) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
59,12
( -1,42% )
Gebot
58,23
Fragen
59,45
Volumen
1.528.363
Durchschnittliches Volumen (3 Mio.)
US$ 2.055.217
Finanzvolumen
US$ 90.502.629
58,44 Tagesbereich 60,275
49,2592 52-Wochen-Bereich 66,275
Marktkapitalisierung
Unternehmenswert
10,619B
Handelsende
59,97
Handelsbeginn
60,15
Letzte Trade
1
@
59.42
Letzter Handelszeitpunkt
00:48:03
VWAP
59,2154
Erlöse (LTM)
3,24B
Nettogewinn (LTM)
268,74M
Ausgegebene Aktien
193.284.438
Streubesitz (%)
99,38%
Institutioneller Besitz (%)
100,07%
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
42,24
Kurs-Umsatz-Verhältnis (KUV)
3,52
Gewinn pro Aktie (EPS)
1,4
Beta
0,24

Über BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products i... BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California. Mehr anzeigen

Sektor
Health Care
Branche
-
Hauptsitz
San Rafael, United States
Gegründet
1996
BioMarin Pharmaceutical Inc is listed in the Health Care sector of the NASDAQ with ticker BMRN. The last closing price for BioMarin Pharmaceutical was US$59,97. Over the last year, BioMarin Pharmaceutical shares have traded in a share price range of US$ 49,2592 to US$ 66,275.

BioMarin Pharmaceutical currently has 193.284.438 shares in issue. The market capitalisation of BioMarin Pharmaceutical is US$11,43 billion. BioMarin Pharmaceutical has a price to earnings ratio (PE ratio) of 42.24.

BMRN Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.40.68119891008258.7260.6757.545144904359.64850474CS
43.586.4458048253555.5460.6754.26190579257.24305221CS
124.618.4571638231554.5160.6749.2592210471854.98581344CS
260.160.27137042062458.9666.27549.2592205302256.65608621CS
52-0.45-0.75541379889259.5766.27549.2592225942656.30517597CS
156-25.97-30.520625220485.0999.5649.2592190335868.78838768CS
260-24.72-29.484732824483.84117.7749.2592165787274.94084119CS

BMRN - Frequently Asked Questions (FAQ)

What is the current BioMarin Pharmaceutical Inc share price?
The current share price of BioMarin Pharmaceutical Inc is US$ 59,12
How many BioMarin Pharmaceutical Inc shares are in issue?
BioMarin Pharmaceutical Inc has 193.284.438 shares in issue
What is the market cap of BioMarin Pharmaceutical Inc?
The market capitalisation of BioMarin Pharmaceutical Inc is USD 11,43B
What is the 1 year trading range for BioMarin Pharmaceutical Inc share price?
BioMarin Pharmaceutical Inc has traded in the range of US$ 49,2592 to US$ 66,275 during the past year
What is the PE ratio of BioMarin Pharmaceutical Inc?
The price to earnings ratio of BioMarin Pharmaceutical Inc is 42,24
What is the cash to sales ratio of BioMarin Pharmaceutical Inc?
The cash to sales ratio of BioMarin Pharmaceutical Inc is 3,52
What is the registered address of BioMarin Pharmaceutical Inc?
The registered address for BioMarin Pharmaceutical Inc is 770 Lindaro Street, San Rafael, California, 94901
What is the BioMarin Pharmaceutical Inc website address?
The website address for BioMarin Pharmaceutical Inc is www.biomarin.com

BMRN Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen